A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients With Cirrhosis and Refractory Ascites

Summary

This study evaluates the addition of BIV201 (terlipressin diacetate) as a continuous infusion in addition to standard of care (diuretics and therapeutic paracentesis) for reduction of ascites and complications in adult patients with refractory ascites secondary to decompensated cirrhosis

Timeline

Start

2021-06-17

Primary completion

2023-05-08

Completion

2023-05-08

Outcome

Outcome not reported

Stopped: “For reasons unrelated to safety or efficacy”

Drugs

Indications